Develops targeted medicines for patients with cancers driven by RAS mutations, including pancreatic, lung and colorectal cancers.
10-K for FY2025, filed Feb 25, 2026
The company works with collaborators through agreements covering licenses and research and development, which may also include product delivery and other joint work.
10-K for FY2025, filed Feb 25, 2026The Company enters into collaboration agreements under which it may obtain upfront license fees, research and development funding, and…View ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
−$407.5MView ↗
8-K, filed Aug 26, 2026
On August 26, 2026, the U.S. Food and Drug Administration approved RASONQUE™ (daraxonrasib) for the treatment of adult patients with…View ↗
Pipeline focus
The older report described RAS inhibitors alongside companion inhibitors aimed at other signaling pathway targets. The latest report describes a pipeline centered on RAS inhibitors.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 25, 2026Our research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which we refer to as RAS(ON)…View ↗
Competes with Amgen, Betta Pharmaceuticals, BMS, Chengdu Huajian Future Technology, D3 BIO, Eli Lilly, GenEros Biopharma, GenFleet Therapeutics, Genhouse Bio, Guangzhou BeBetter Medicine Technology, HUYA Bioscience, InventisBio, Jacobio Pharmaceuticals, Jiangsu Hansoh Pharmaceutical Group, Merck, Sharpe & Dohme, Roche/Genentech, BridgeBio Pharma, Frontier Medicines, AstraZeneca, and Incyte
10-K for FY2025, filed Feb 25, 2026There are several programs in clinical development targeting KRAS G12C, including programs directed at KRAS(OFF) G12C being conducted by…View ↗
Loading...